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Abstracts / Journal of Nutrition & Intermediary Metabolism 1 (2014) 1e55 13conﬁdent’ (50.5%) to ‘very conﬁdent’ (15.5%) in providing nutritional rec-
ommendations; around one-third (29.0%) were ‘somewhat conﬁdent’.
Conclusions: Despite their conﬁdence in providing advice, GP trainees
demonstrated incomplete knowledge of nutritional recommendations.
Medical schools must provide doctors with crucial nutritional knowledge
to help prevent chronic disease in the community.
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Background/Aims: To estimate the efﬁcacy of a probiotic yogurt
compared to a pasteurised yogurt for the prevention of antibiotic-associ-
ated diarrhoea in children.
Methods: This was a multisite, randomised, double-blind, placebo-
controlled clinical trial conducted between 2009-2012. Children aged 1-12
years on antibiotics were randomised to receive 200 g/day of either yogurt
(probiotic) containing Lactobacillus rhamnosus GG® (LGG®), Biﬁdobacterium
lactis® (Bb-12®) and Lactobacillus acidophilus® (La-5®) or apasteurizedyogurt
(placebo) for the duration of their antibiotic treatment. Stool frequency, and
consistency were recorded for the duration of treatment plus one week.
Primary outcomewas stool frequency and consistency, classiﬁed at different
levels of diarrhoea severity. Due to small number of cases of diarrhoea,
comparisons between groups were made using Fisher’s exact analysis.
Results: Seventy children completed the trial (36 placebo and 34 pro-
biotic). There were no incidents of severe diarrhoea (stool consistency 6,
 3 stools/day for  2 consecutive days) in the probiotic group and six in
the placebo group (p ¼ 0.025). There was also only one episode of minor
diarrhoea (stool consistency  5,  2 stools/day for  2 days) in the pro-
biotic group compared to 21 in the placebo group (p < 0.001). Probiotic
group reported fewer (one abdominal pain, one vomiting, one headache)
adverse events than the placebo group (six abdominal pain, four loss of
appetite, one nausea).
Conclusions: A yogurt combination of LGG®, La-5® and Bb-12® is an
effective method for reducing the incidence of antibiotic-associated diar-
rhoea in children.
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Background/Aims: Gastrointestinal symptoms (GIS) and dermatological
injuries (DI) are commonly reported after endurance running. The current
studyaimed todeterminewhetherGIS andDI inﬂuencesnutritional intakeof
ultra-runners during a 230 km multi-stage ultra-marathon (MSUM) con-
ducted in hot conditions (32-40 ºC) and a 24-hours continuous (122-208 km
range) ultra-marathon (24h) conducted in temperate conditions (0-20 ºC).
Methods: Ad libitum food and ﬂuid intakes of ultra-runners (MSUM n ¼
74, 24h n ¼ 25) were recorded throughout competition in real-time and
analysed by dietary analysis software. A GIS and DI medical log was used to
monitor symptoms throughout both events. ANOVA was used to analyse
nutritional intake data between no-GIS vs. GIS, no-DI vs. DI; and severity of
symptoms and injuries.
Results: GIS were reported by 85% and 65% of ultra-runners throughout
MSUM and 24h, respectively. GIS during MSUM resulted in reduced total
daily, pre-stage, during, and post-stage energy (p¼ 0.04) andmacronutrientintakes (p ¼ 0.02); whereas GIS during 24h did not inﬂuence nutritional
variables. ThroughoutMSUMand24h, 76%and12%of ultra-runners required
medical intervention for DI, respectively. DI during MSUM resulted in
reduced total daily energy intake (p ¼ 0.05), carbohydrate (p ¼ 0.045) and
ﬂuid (p ¼ 0.016) intake during running, and protein intake post-stage (p ¼
0.045).DI throughout24hwas low, thus comparative analyseswasnot viable.
Conclusions: High rates of GIS were reported in both events; however GIS
only affected nutritional intake during MSUM, likely attributed to exer-
tional-heat stress. DI presence and severity reduce nutritional intake
during running and recovery in MSUM, suggesting DI prevention strate-
gies are warranted.
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GLOBAL GENE TRANSCRIPT PROFILING REVEALS LACTOFERRIN
INTERVENTION INFLUENCES NEURAL DEVELOPMENT AND COGNITION
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Background/Aims: To test the hypothesis that lactoferrin (Lf) may induce
gene expression proﬁling and function to improve neurodevelopment and
cognition in postnatal piglets, an animal model for human infants.
Methods: Three-day-old male piglets were randomly allocated to two
groups. Group 1were fedmilk replacer supplemented with Lf at 0.6 g/L (n¼
17) and Group 2, 0.06 g/L (n ¼ 16; control). RNA was isolated from the hip-
pocampus of 10 piglets/group and subjected to transcript proﬁling using a
Porcine Affymetrix GeneChips representing 20,201 genes from Sus scrofa. A
TaqMan®Geneexpressionassaybasedreal-timePCRwasused tovalidate the
microarray ﬁndings. Results were analysed using Partek Genomics Suite 6.5
software and Ingenuity System (Ingenuity® System, Redwood City, CA, USA).
Results: A total of 1,187 genes were differentially expressed between the
control and Lf groups, based on our ﬁlter criteria (fold change: 1.15 and p <
0.05). A positive global effect of Lf on neurodevelopment and cognition
was observed, as evidenced by the modulation of a wide range of neuronal
processes including an increase in cellular protrusions, microtubule dy-
namics, formation and organization of neurite outgrowth, cytoskeleton
formation, and a decrease in anxiety. TaqMan® gene expression assays
which showed that Lf up-regulated the brain-derived neurotrophic factor
(BDNF) gene and signalling pathway known to inﬂuence early neuro-
development and cognition in postnatal mammals.
Conclusions: Lf supplementation up-regulated several canonical signal-
ling pathways associated with neurodevelopment and cognition, the
principal one being BDNF.
Funding source(s): Medical school of Xiamen University, China, Nestle
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BITTER TASTE PHENOTYPE BETTER PREDICTS FOLATE STATUS THAN
TAS2R38 BITTER RECEPTOR GENOTYPE ALONE IN A COLONOSCOPY
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Background/Aims: TAS2R38 polymorphisms inﬂuence bitter taste
perception. Those sensitive to bitter tastes may consume less healthy
vegetables, resulting in a higher risk of diet-related disease. We assessed
the inﬂuence of TAS2R38 genotype and bitter taste phenotype on folate
intake and blood levels, as a marker of healthy vegetable consumption, and
if this inﬂuenced risk of adenomatous polyps (AP).
Methods: Blood was collected from colonoscopy patients (n ¼ 206).
Polymorphisms in the TAS2R38 gene were measured (Restriction fragment
length polymorphism-PCR/sequencing; A49P; rs713598, V262A: rs1726866,
